Stoke Therapeutics shared details from their earnings call for the third quarter of 2026.

Oct 29, 2026, 7:55 PM ETResultsRead the original at Benzinga

Good for STOK

Stoke said 110 of 162 patients reached week 28 with no treatment stops, and the FDA accepted a multi-part measure of behavior and thinking. The $73.6 million quarterly loss and lack of seizure results temper the news, but cash expected through early 2028 supports continued progress.

STOK · Stoke Therapeutics

AI read · Good for STOK

The AI's read

That FDA discussion makes the planned filing clearer, and patient retention shows the study is progressing. Cash is expected to cover operations until early 2028. Still, the call reported no seizure results, so the study has not yet shown that zarepinersen works. The quarterly loss adds concern, but the cash gives Stoke time to reach the next readout.

Get alerts for STOK

Follow Stoke Therapeutics (STOK) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for STOK

Free on the App Store and Google Play, or on the web.